Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NetraMark Holdings Inc C.AIAI

Alternate Symbol(s):  AINMF

Healthcare Medical Devices
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several... see more

Recent & Breaking News (CSE:AIAI)

NUROSENE'S CHIEF SCIENTIFIC OFFICER TO PRESENT AT WORLD ORPHAN DRUG CONGRESS USA 2022

Canada NewsWire June 8, 2022

NUROSENE ENTERS INTO AGREEMENT WITH A SPECIALTY BIOPHARMA COMPANY TO GENERATE INSIGHTS FROM CLINICAL TRIAL RESULTS

Canada NewsWire May 27, 2022

NUROSENE'S CHIEF SCIENTIFIC OFFICER PUBLISHES PAPER ON AI AND PLACEBO RESPONSE

Canada NewsWire May 19, 2022

Nurosene Completes Population Stratification Project For Major Pharmaceutical Company

Canada NewsWire May 18, 2022

NUROSENE ANNOUNCES STRATEGIC AGREEMENT WITH BRAIN ANALYSIS PLATFORM, COVE NEUROSCIENCES INC.

Canada NewsWire May 6, 2022

Nurosene Initiates Research on Nuro App in Collaboration with Dalhousie University

Canada NewsWire April 19, 2022

NUROSENE ANNOUNCES RESEARCH PARTNERSHIP IN ONCOLOGY WITH THE ONTARIO INSTITUTE FOR CANCER RESEARCH

Canada NewsWire April 13, 2022

NUROSENE APPOINTS SEASONED FINANCIAL EXECUTIVE GINO DEMICHELE TO BOARD OF DIRECTORS

Canada NewsWire April 7, 2022

Nurosene's CSO And Director Of Bioinformatics Receives 'Highly Cited Paper' Award For AI-Based Alzheimer's Research Findings

Canada NewsWire March 8, 2022

NUROSENE ADVANCES BRAIN HEALTH WITH THE LAUNCH OF ITS SCIENCE-FIRST NURO APP

Canada NewsWire March 1, 2022

Nurosene Announces A Change in Leadership

PR Newswire February 23, 2022

NUROSENE LAUNCHES NETRAPLACEBO, AN INNOVATIVE AI TECHNOLOGY TO IMPACT CLINICAL TRIAL SUCCESS RATES IN THE US$94B CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET.(1)

PR Newswire February 17, 2022

IIROC Trade Resumption - MEND

PR Newswire February 10, 2022

NUROSENE & CYCLICA PARTNER TO DEVELOP NOVEL DRUGS FOR NEURODEGENERATIVE DISEASES

PR Newswire February 10, 2022

IIROC Trading Halt - MEND

PR Newswire February 10, 2022

Nurosene Health Inc. Announces Change to its Board of Directors

PR Newswire February 4, 2022

Nurosene Announces Research Partnership designed to Accelerate and Identify Novel Drug Candidates for its IP Portfolio

PR Newswire January 27, 2022

Nurosene Health Inc. Reports 2021 Annual Financial Results and Provides Shareholder Update

PR Newswire January 26, 2022

Nurosene to Present at the H.C. Wainwright Bioconnect Virtual Investor Conference on January 10-13, 2022

PR Newswire January 6, 2022

NUROSENE CSO AWARDED FOR RESEARCH ON PLACEBO RESPONSE RELATED TO MENTAL HEALTH

PR Newswire December 16, 2021